185 related articles for article (PubMed ID: 26565547)
1. Odontoiatric perspectives and osteonecrosis of the jaw as a possible adverse effect of bisphosphonates therapy in fibrous dysplasia and McCune-Albright syndrome.
Tessaris D; Matarazzo P; Lala R; Defabianis P
J Pediatr Endocrinol Metab; 2016 Mar; 29(3):333-6. PubMed ID: 26565547
[TBL] [Abstract][Full Text] [Related]
2. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia.
Majoor BC; Appelman-Dijkstra NM; Fiocco M; van de Sande MA; Dijkstra PS; Hamdy NA
J Bone Miner Res; 2017 Feb; 32(2):264-276. PubMed ID: 27649526
[TBL] [Abstract][Full Text] [Related]
3. EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE.
Wang Y; Wang O; Jiang Y; Li M; Xia W; Meng X; Xing X
Endocr Pract; 2019 Jan; 25(1):23-30. PubMed ID: 30383490
[TBL] [Abstract][Full Text] [Related]
4. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
5. Risk of developing spontaneous MRONJ in fibrous dysplasia patients treated with bisphosphonates: a systematic review of the literature.
Nadella S; Mupparapu M; Akintoye SO
Quintessence Int; 2022 Jun; 53(7):616-623. PubMed ID: 35674165
[TBL] [Abstract][Full Text] [Related]
6. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome.
Leet AI; Chebli C; Kushner H; Chen CC; Kelly MH; Brillante BA; Robey PG; Bianco P; Wientroub S; Collins MT
J Bone Miner Res; 2004 Apr; 19(4):571-7. PubMed ID: 15005844
[TBL] [Abstract][Full Text] [Related]
7. Dental perspectives in fibrous dysplasia and McCune-Albright syndrome.
Akintoye SO; Boyce AM; Collins MT
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Sep; 116(3):e149-55. PubMed ID: 23953425
[TBL] [Abstract][Full Text] [Related]
8. Fibrous dysplasia & McCune-Albright syndrome: an experience from a tertiary care centre in north India.
Bhadada SK; Bhansali A; Das S; Singh R; Sen R; Agarwal A; Mittal BR; Nahar U; Dutta P; Khandelwal N
Indian J Med Res; 2011 May; 133(5):504-9. PubMed ID: 21623035
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate-induced zebra lines in fibrous dysplasia of bone: histo-radiographic correlation in a case of McCune-Albright syndrome.
Corsi A; Ippolito E; Robey PG; Riminucci M; Boyde A
Skeletal Radiol; 2017 Oct; 46(10):1435-1439. PubMed ID: 28660402
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G
Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788
[TBL] [Abstract][Full Text] [Related]
11. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
Mavrokokki T; Cheng A; Stein B; Goss A
J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
[TBL] [Abstract][Full Text] [Related]
12. Clinical and radiological observations in a case series of 26 patients with fibrous dysplasia.
Thomsen MD; Rejnmark L
Calcif Tissue Int; 2014 Apr; 94(4):384-95. PubMed ID: 24390518
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
Brown JJ; Ramalingam L; Zacharin MR
Clin Endocrinol (Oxf); 2008 Jun; 68(6):863-7. PubMed ID: 18221397
[TBL] [Abstract][Full Text] [Related]
14. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients.
Favia G; Pilolli GP; Maiorano E
J Rheumatol; 2009 Dec; 36(12):2780-7. PubMed ID: 19884275
[TBL] [Abstract][Full Text] [Related]
15. Eight-year follow-up of a girl with McCune-Albright syndrome.
Aycan Z; Önder A; Çetinkaya S
J Clin Res Pediatr Endocrinol; 2011; 3(1):40-2. PubMed ID: 21448334
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
17. [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome].
Pfeilschifter J; Ziegler R
Med Klin (Munich); 1998 Jun; 93(6):352-9. PubMed ID: 9662942
[TBL] [Abstract][Full Text] [Related]
18. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.
Rizzoli R; Burlet N; Cahall D; Delmas PD; Eriksen EF; Felsenberg D; Grbic J; Jontell M; Landesberg R; Laslop A; Wollenhaupt M; Papapoulos S; Sezer O; Sprafka M; Reginster JY
Bone; 2008 May; 42(5):841-7. PubMed ID: 18314405
[TBL] [Abstract][Full Text] [Related]
19. Polyostotic Fibrous Dysplasia With and Without McCune-Albright Syndrome-Clinical Features in a Nordic Pediatric Cohort.
Utriainen P; Valta H; Björnsdottir S; Mäkitie O; Horemuzova E
Front Endocrinol (Lausanne); 2018; 9():96. PubMed ID: 29599748
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?
Lesclous P; Abi Najm S; Carrel JP; Baroukh B; Lombardi T; Willi JP; Rizzoli R; Saffar JL; Samson J
Bone; 2009 Nov; 45(5):843-52. PubMed ID: 19631301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]